Insights
Insights From Our Experts
Articles
Advancing Medical Affairs Through Data and Scientific Communications: Key Takeaways from DIA MASC 2026
At the 2026 DIA Medical Affairs and Scientific Communications (MASC) Forum, EVERSANA shared new thought leadership focused on how medical affairs teams can strengthen decision‑making, optimize operations, and elevate scientific communications in an increasingly data‑driven environment.…
Scaling Practical AI Across Commercial Teams
EVERSANA’s AI journey began with classic predictive modeling but its evolution into an enterprise-wide strategy is rooted in something deeper: a trusted data foundation and rigorous change management. Drew McCormick, Head of Data & Analytics at EVERSANA, explains how…
Key Implications of Recent U.S. PBM Reforms
PBM Reform Is Here—What It Means for Manufacturers and Plan Sponsors Recent U.S. policy actions are reshaping the pharmacy benefit manager landscape. New federal legislation, a proposed Department of Labor rule, and a landmark FTC settlement…
Building a scalable GLP-1 care model
The rapid rise of GLP‑1 therapies has revealed a fundamental challenge across healthcare. For many patients, the pathway to their first prescription is not a single, unified entry point. It’s a maze of primary care visits, telehealth platforms,…
Navigating the Intersection of AI, Global Commercialization and Patient Value
Artificial intelligence is reshaping the life sciences industry, but meaningful progress comes when technology is paired with human judgment, regulatory discipline and a clear focus on patient value. In a recent EU Startup News interview, our own Faruk Capan,…
Recognizing Rare Disease Day: Advancing Hope, Access and Innovation
On Rare Disease Day, we recognize the more than 300 million people worldwide living with rare conditions—individuals who often face long diagnostic journeys, limited treatment options, and barriers to consistent care. At EVERSANA, supporting this community is…
Why Our AI Agency Is So Much More Than ChatGPT for Life Sciences Marketing
AI is everywhere. We can generate emails, social posts, videos and research in seconds. But as Faruk Capan explains in his PM360 article, life sciences marketing requires more than a simple AI tool. It requires speed, compliance, security and human expertise working together. …
Demonstrating the Clinical and Economic Value of Efgartigimod for AChR‑Positive gMG in Canada
Generalized myasthenia gravis (gMG) is a rare autoimmune neuromuscular disease that leads to fluctuating muscle weakness and fatigue, often disrupting daily life. Even with standard therapies, many patients continue to experience persistent symptoms or medication‑related side…
Inside the Shifting Role of Pharma 3PLs: Resilient, Regulated & Ready
Third-party logistics in the pharmaceutical industry must always be considered a strategic partnership, not a transactional handoff. Today’s 3PL is no longer about outsourcing a non-core function. It is about orchestrating a regulated, data-rich, end-to-end value chain. Danny Williams, President of Channel Management &…
EVERSANA Recognized by Vault for the Fifth Consecutive Year
EVERSANA has been recognized by Vault for the fifth consecutive year in its 2026 Consulting Rankings, earning placement in both the: Vault Consulting 50 – North America Health Sciences Consulting category Vault’s annual rankings are informed by verified consultant feedback across the…